​​The strategy of 2017 picking will be the same as in 2016. The biotech stocks will be categorized into several groups: I) short-term investment (this will include biotech scams that can be pumped in nearest future); II) biotech gems that have strong science basis and pps below $15, potential buyouts targets for Big Pharmas; III) big cap biotechs for long-term investment (3 and more years)

I.
1) AXON (can play on potential "run up" but sell before phase III results release)
2) ORMP (Phase 3 start can induce short run up so buying before at $6-6.50 is not bad idea)
3) AVXL (just SELL this scam)
4) NTRP (biotech scam​ that will be pumped because "success" of AD drug in Ph2 trial and promises to proceed to Ph3 trial)


II.
1) CARA is still BUY, good phase 3 results for IV pain-killer can induce +50-60% spike)
2) SGYP buy and hold
3) RGNX (BUY)
4) MTNB (buy at low and HOLD, 05/17/17 update STRONG BUY below $3 and up to $3.50 )
5) CTIX​​​
6) AGTC (accumulate at low pps and HOLD)
7) CERS​​ (STRONG BUY)
​8) SYN
9) ​EDAP
10) ​OSIR  (buy at low pps $5-5.50 and HOLD before release of 2015-2016 results release)
11) NYMX​
12) VBLT
13) CLDX
14) NDRM
15) LXRX​​ 
16) AKAO (very high (>70%) probability of acquisition by Big Pharma in 2017)
17) CNAT
18) MRUS
19) AKBA
20) IDRA​
21) KURA
22) NERV​​
23) AMRN (can be strong pps spike after Phase 3 ​REDUCE-IT cardiovascular outcomes results release in 2018, pps $3-3.5 is good for entry) 
24) PTCT (long, pps "run up" before FDA advisory meeting in September is possible to up to $20)
25) AVEO (buyout target for Big Pharma in 2017, possible upside +200%)​
26) MBRX (STRONG BUY, ​strong science, very good portfolio)
27) AUPH (Ph3 Active Lupus With Voclosporin will drive pps +50-70% during next 1-2 years)
28) SRNE
​29) ZIOP
30) BLCM
​​
​​III.

1) NVO (buy at current low for LONG, new oral GLP-1 pills will be a major breakthrough in diabetes treatment)
2) MKGAY (Sigma-Aldrich acquisition increased cash flow at least +25%, licensing of new drugs and technologies)
3) ACAD
4) ​ALKS
5)​ EXEL
6) GBT​
7) IONS​
8) KITE
9) ARRY (potential buyout target for BF after FDA approval of cancer drug in June 2017)
10) SGEN
11) IRWD 
12) MYGN ​
13) AERI
14) RARE​​
15) JUNO​
16) AIMT​
to be continued...

I will avoid in 2017:

1) AXON
2) BLUE
3) PRAN
4) XON
5) XOMA
6) EDIT
7) ​​NTRP (recent AD drug scam biotech, STRONG SELL or SHORT)

Sign-Up  |  Log-In